[HTML][HTML] Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of …
A Zhu, P Yuan, N Hu, M Li, W Wang… - Cancer Biology & …, 2021 - ncbi.nlm.nih.gov
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has
been shown to produce an objective response in patients with pretreated mBC. Oral …
been shown to produce an objective response in patients with pretreated mBC. Oral …
The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer
JY Huang, XL Chen, XF Xie, L Song, LP Chen… - Cancer …, 2024 - Wiley Online Library
Background Apatinib is an oral small‐molecule tyrosine kinase inhibitor that blocks vascular
endothelial growth factor receptor‐2. Oral vinorelbine is a semisynthetic chemotherapeutic …
endothelial growth factor receptor‐2. Oral vinorelbine is a semisynthetic chemotherapeutic …
Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer
X Hu, J Cao, W Hu, C Wu, Y Pan, L Cai, Z Tong… - BMC cancer, 2014 - Springer
Background Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth
factor receptor 2 (VEGFR-2). This study was conducted to assess the efficacy and safety of …
factor receptor 2 (VEGFR-2). This study was conducted to assess the efficacy and safety of …
[HTML][HTML] Application of apatinib after multifaceted therapies for metastatic breast cancer
J Wang, Y Chen, R Chen, L Wu… - Translational Cancer …, 2020 - ncbi.nlm.nih.gov
Background Apatinib is a small molecule tyrosine kinase inhibitor (TKI) that is taken orally
and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This …
and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This …
[HTML][HTML] Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
R Zhang, Y Chen, X Liu, X Gui, A Zhu, H Jiang… - Frontiers in …, 2023 - frontiersin.org
Objectives: This study evaluated the efficacy and safety of apatinib (an oral small-molecule
tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in …
tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in …
A real-world multicentre retrospective study of low-dose apatinib for human epidermal growth factor receptor 2-negative metastatic breast cancer
T Zeng, C Sun, Y Liang, F Yang, X Yan, S Bao… - Cancers, 2022 - mdpi.com
Simple Summary There are limited treatments for patients with HER2-negative breast
cancer, especially for patients with metastatic breast cancer. This study aimed to observe the …
cancer, especially for patients with metastatic breast cancer. This study aimed to observe the …
[HTML][HTML] Real-world data on apatinib efficacy-results of a retrospective study in metastatic breast cancer patients pretreated with multiline treatment
Z Liu, J Shan, Q Yu, X Wang, X Song, F Wang… - Frontiers in …, 2021 - frontiersin.org
Objectives The NCCN guidelines recommend that the addition of bevacizumab should be
considered in metastatic breast cancers in some circumstances, but there are no …
considered in metastatic breast cancers in some circumstances, but there are no …
[HTML][HTML] A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer
N Hu, A Zhu, Y Si, J Yue, X Wang, J Wang, F Ma… - Frontiers in …, 2021 - frontiersin.org
Introduction We performed this clinical trial to evaluate the efficacy and safety of apatinib and
oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer …
oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer …
Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment
Y Lin, Z Wu, J Zhang, X Hu, Z Wang, B Wang… - Tumor …, 2017 - journals.sagepub.com
Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor
receptor 2. This study aimed to evaluate the efficacy and safety of apatinib in metastatic …
receptor 2. This study aimed to evaluate the efficacy and safety of apatinib in metastatic …
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
DD Li, Z Tao, BY Wang, LP Wang, J Cao, XC Hu… - NPJ Breast …, 2022 - nature.com
While therapies such as chemotherapy combined with immunotherapy, sacituzumab
govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression …
govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression …
Related searches
- oral vinorelbine apatinib in combination
- oral vinorelbine clinical implications
- oral vinorelbine breast cancer
- clinical implications apatinib in combination
- breast cancer apatinib in combination
- breast cancer clinical implications
- breast cancer multicenter phase
- breast cancer neratinib capecitabine
- breast cancer chemotherapy in patients
- breast cancer trial setting
- breast cancer biomarker analysis
- breast cancer growth factor
- breast cancer efficacy of apatinib
- breast cancer oral etoposide
- breast cancer capecitabine in patients
- breast cancer lapatinib capecitabine